Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 2 % of short-term debt in 2025; threshold 65 %.
-
Busy address KBO
19 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Pledge Therapeutics from Leuven, company number BE0726743301, closed financial year 2025 with a result of € -1.4 million after tax. For that financial year Pledge Therapeutics recorded a gross margin of € -644,682 and equity of € -3.8 million. Compared with financial year 2024, the result moved from € -688,788 to € -1.4 million. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on October 15, 2026.
€ -3.8 million
▼ € 1.4 million vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -1.4 million
▼ 103 % more loss than in 2024
Profit after tax over the fiscal year.
€ 40,488
▲ 15% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -3.8 million.
People and assets in 2025
6.6
▲ 0.7 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 636,727
▲ 16% vs 2024
€ 96,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 185,695
▲ € 162,430 vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 135,787
▲ 34% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -88,925 | € -144,155 | € -97,474 | € -644,682 | ▼ € 547,208 |
| Profit after taxes | € -408,469 | € -558,654 | € -688,788 | € -1,400,905 | ▼ € 712,116 |
| Equity | € -1,148,807 | € -1,707,462 | € -2,396,250 | € -3,797,155 | ▼ € 1.4 million |
| Total debts | € 1,492,990 | € 2,068,781 | € 2,688,672 | € 4,027,009 | ▲ 50% |
| Cash | € 48,876 | € 82,500 | € 35,210 | € 40,488 | ▲ 15% |
| Retained profit | € -1,149,307 | € -1,707,962 | € -2,396,750 | € -3,797,655 | ▼ € 1.4 million |
| Balance sheet total | € 344,183 | € 361,319 | € 292,422 | € 229,854 | ▼ 21% |
| Employees (FTE) | 3.5 | 4.1 | 5.9 | 6.6 | ▲ 0.7 |
Key figures of Pledge Therapeutics, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Pledge Therapeutics?
What happened at Pledge Therapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 1.4 million. filed late Source: NBB ↗
- Ali MUNAWAR became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 408,469 loss in 2022 to € 1.4 million loss in 2025.
Management
Behind Pledge Therapeutics is Ali MUNAWAR.
Directors
According to the 2025 annual accounts
Ali MUNAWAR
Director
since 2019
Establishments
Establishment units
Physical locations of this company
Gaston Geenslaan 1
3001 Leuven
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 19 companies are registered at this address.
All companies at this address →reMYND
€ -217,249 gross margin · 2025
DName-iT
€ -71,430 gross margin · 2025
miDiagnostics
€ 24,934 revenue · 2025
PALEO
€ 1.5 million gross margin · 2025
Fishway
€ 413,084 gross margin · 2025
+14 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Self-hosted
Hosting
BELNET, BE
Domain
Domain
bioincubator.be
Registered
2007-04-02
Website info
Features
Security
Network
Details
- Company number
- 0726.743.301
- VAT number
- BE 0726.743.301
- Registered office
- Gaston Geenslaan 1, 3001 Leuven
- Names & denominations
- Pledge Therapeutics · Pledge Tx
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 14 May 2019
- Peppol
- Active · Active since 7 Apr 2026
- Contact
- bioincubator.be
- Activities · NACE
Vervaardiging van farmaceutische grondstoffen